Radiopharm Theranostics Ltd (RADX) Short term Debt (2024 - 2026)

Radiopharm Theranostics (RADX) has reported Short term Debt for 3 consecutive years, with $48667.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt rose 122.11% year-over-year to $48667.7 in Q2 2026; TTM through Jun 2026 was $48667.7, a 122.11% increase from a year earlier, with the FY2026 full-year figure at $46596.1, down 98.64% from the prior year.
• Short term Debt was $48667.7 for Q2 2026 at Radiopharm Theranostics, up from $21911.4 in the prior quarter.
• Over five years, Short term Debt peaked at $2.2 million in Q4 2024 and troughed at $21911.4 in Q2 2025.
• A 3-year average of $588587.8 and a median of $45156.3 in 2024 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt plunged 47.39% in 2025 and surged 122.11% in 2026, its largest moves.
• Over 3 years, Short term Debt stood at $2.2 million in 2024, then sank by 99.02% to $21911.4 in 2025, then jumped by 122.11% to $48667.7 in 2026.
• The last three Short term Debt figures came in at $48667.7 (Q2 2026), $21911.4 (Q2 2025), and $2.2 million (Q4 2024), per Business Quant data.